Eli Lilly and Company (NYSE:LLY) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Shares of Eli Lilly and Company (NYSE:LLY – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the twenty-one brokerages that are presently covering the stock, ...
The Hong Kong company saw a reduction in body weight across both cohorts with no serious adverse events reported.
Eli Lilly and Company's latest 10-K report for the year ended December 31, 2024, reveals significant financial growth. The company reported a revenue of $45,042.7 million, marking a 32% increase from ...
Popular weight-loss therapies like Novo Nordisk's Wegovy and Eli Lilly's Zepbound result in both fat and muscle loss.
About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, ...
Weight loss injections have become incredibly popular in the last year or so. In fact, these medications are so widely used ...
Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2024 investor letter. The ...
Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. | Ascletis Pharma’s ...
President Trump is going scorched earth on America’s major European trading partners. Vowing to impose reciprocal tariffs on ...
Ireland's pharmaceutical industry shipped billions' worth of goods to the U.S., but face threats from Trump 2.0.
Glucagon-like peptide receptor agonists (GLP-1RAs) like Novo Nordisk’s semaglutide (Ozempic, Wegovy) and Eli Lilly’s ...
The Fund lagged the benchmark composite index, which was up 15.01%, while the Fund underperformed the Morningstar Moderate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results